Buy a Pullback in Neurocrine After Q3 Beat – Research Engine Still Undervalued

Hook + thesis

Neurocrine Biosciences (NBIX) surprised again on 11/03/2026 with Q3 adjusted EPS of $3.29 and revenue of $1.12 billion, both comfortably above consensus. Management raised its 2026 Ingrezza sales outlook to $2.90–$2.925 billion after $801 million in Ingrezza sales in the quarter. The market rewarded the print, but intraday momentum and an elevated RSI mean this is a trade to enter on a pullback rather than chase.

Thesis in one line: fundamental momentum (double-digit Ingrezza growth + hypergrowth in Crenessity) plus free cash flow generation supports a mid-term long: buy a measured dip near $162 with a stop at $150 and a target at $190 over the next 45 trading days.

Why the market should care - business snapshot and fundamentals

Neurocrine is a specialty neuroscience biotech with a commercial portfolio anchored by Ingrezza (tardive dyskinesia), a fast-growing newer franchise Crenessity, and other products such as Vykat XR. Q3 revenue was $1.12 billion, up 41.2% year-over-year, and adjusted EPS came in at $3.29. Ingrezza delivered $801 million in quarterly sales (+17% y/y) while Crenessity surged 115% to $211 million. Management raised full-year Ingrezza sales guidance to $2.90–$2.925 billion, signaling durable demand and healthy prescription dynamics.

The company is not just growing revenue; it is converting sales into cash. Free cash flow for the company is roughly $1.04 billion on an enterprise value of about $16.12 billion, implying a healthy FCF profile relative to market cap of $16.76 billion. At current valuation multiples, investors are buying growth with reasonable cash conversion.

Key financial and valuation cues

How the numbers support the trade

The arithmetic is straightforward: the company is growing top line at >40% y/y in the most recent quarter and generating roughly $1.04 billion in free cash flow. That cash flow implies an FCF yield in the mid-single digits today (FCF / market cap). On a mid-term horizon, if growth holds and newer franchises continue scaling, the multiple can expand modestly from current EV/EBITDA ~16.2x and price-to-earnings in the mid-20s. The business is funding growth internally and is less dependent on dilutive capital raises, which reduces one major execution risk for growth biotech names.

Technical context and trade mechanics

Technically, NBIX shows bullish momentum: MACD histogram is strongly positive and the stock has recently run above its 10/20/50-day moving averages. That said, the RSI is elevated near 76, indicating short-term overbought conditions and a higher probability of a pullback or consolidation. Average daily volume is roughly 1.48 million shares while today’s volume spiked to over 4 million, suggesting heavy headline-driven trading.

Given this mix, a disciplined approach is warranted: buy the first realistic pullback into the $160–$164 area rather than chasing strength above yesterday’s intraday high. Use a tight stop under a structurally important level to cap downside and a target above $185 where multiples begin to look richer versus reasonable growth assumptions.

Trade plan (actionable)

• Direction: Long
• Entry: Buy at $162.00
• Stop loss: $150.00
• Target: $190.00
• Horizon: mid term (45 trading days) - this window captures the near-term momentum play off the earnings beat, the upgraded Ingrezza guide, and allows time for prescription trends and institutional flows to follow through.

Rationale: Entry at $162 avoids buying the immediate overbought pop while remaining within a reasonable discount to the current price of ~$166. The stop at $150 limits downside to a level that would suggest the beat and guide were already priced in and sentiment has structurally turned negative. The $190 target reflects a mid-teens multiple expansion on expected earnings growth and is reachable if prescription trends and Crenessity momentum continue.

Catalysts to watch (2-5)

• Prescription trends and weekly/monthly Ingrezza scripts - continued record prescriptions would justify multiple expansion.
• Institutional repositioning after the Q3 beat - heavy flows could sustain the rally if insiders/institutions buy into the print.
• Pipeline readouts and trial progress - late-stage programs slated for 2027 (depression, schizophrenia) are longer-term but any positive incremental trial updates will be supportive.
• Guidance updates or analyst revisions - further upward revisions to Ingrezza or company earnings estimates would be a direct upside catalyst.

Risks and counterarguments

Below are the principal risks that could invalidate the trade. I include at least one concrete counterargument to the bullish view.

• GLP and pricing pressure - the competitive landscape for CNS and related specialty drugs is intense; broader pricing pressure in the industry or payer pushback could impair realized revenue growth even if prescriptions rise.
• Execution on newer franchises - Crenessity is growing fast, but scaling commercial uptake sustainably is not guaranteed. Any slowdown or inventory/pharmacy issues would weaken the narrative.
• Macro and sentiment risk - biotech is sensitive to risk-on flows. A broader market pullback or rotation away from growth names would likely compress multiples quickly and hit NBIX even if fundamentals remain solid.
• Valuation sensitivity - the stock is trading at mid-20s P/E and EV/EBITDA ~16. If investor expectations for growth slip, multiples can re-rate downward meaningfully.
• Short interest and volatility - short interest has shown material levels in recent settlements and recent short-volume activity suggests trading can be choppy. That raises both upside squeeze potential and abrupt selling on weak prints.

Counterargument: You could argue that the immediate post-earnings move already prices the beat and the Ingrezza raise; with an RSI near 76 and heavy intraday volume, the safest play might be to wait for a clearer consolidation or for the stock to re-test the 21- or 50-day EMA. If you prefer a lower-risk approach, waiting for a pullback to $150–$155 would provide a better risk/reward, but it also risks missing follow-through if institutions add on strength.

What would change my mind

I will reassess the bullish stance if any of the following happen: 1) next prescription data shows a material deceleration in Ingrezza demand, 2) management withdraws or meaningfully lowers Ingrezza guidance, 3) material negative clinical data emerges for a key pipeline asset, or 4) macro-driven re-rating forces NBIX below the $150 level on collapsing volume—any of which would invalidate the mid-term outlook and argue for closing the position.

Conclusion

Neurocrine checks the boxes for a tactical mid-term long: credible current growth, strong cash flow, and a refreshed guidance trajectory for the company’s flagship. The trade is not risk-free—valuation is not dirt-cheap and technicals are hot—so discipline matters. Buy the near-term dip at $162 with a stop at $150 and a target at $190 over the next 45 trading days, and manage position size around your personal risk tolerance.

Key numbers to keep top of mind: Q3 revenue $1.12B, Ingrezza $801M, Crenessity $211M, market cap $16.76B, free cash flow ~$1.04B, EV/EBITDA ~16.2x.